Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Uptravi (selexipag) and Tyvaso (treprostinil) are both medications used to treat pulmonary arterial hypertension (PAH), but they have some key differences. Uptravi is a prostacyclin agonist taken orally as a tablet or through an intravenous (IV) injection, while Tyvaso is a man-made version of prostacyclin, a hormone your body naturally makes. It is available as an inhalation treatment through a nebulizer or dry powdered inhaler (DPI). Uptravi is taken twice a day, whereas Tyvaso needs to be used four times a day. Uptravi can cause side effects like headache, diarrhea, and nausea, while Tyvaso commonly causes cough, headache, and throat irritation. Additionally, Uptravi can cause excess fluid in the lungs, while Tyvaso can cause low blood pressure and increases the risk of bleeding.
Uptravi (selexipag)
Tyvaso (treprostinil)
Uptravi (selexipag)
Tyvaso (treprostinil)
Summary of Uptravi vs. Tyvaso
Summary for Prostacyclin agonist
Prescription only
Uptravi (selexipag) is a prostacyclin agonist that's used in adults to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the lungs. This medication can help prevent PAH from getting worse and lower the risk for hospitalization. Uptravi (selexipag) is a tablet that's taken by mouth twice per day. It's also available as an intravenous (IV) injection for people who can't take the medication by mouth. The most common side effects include headache, diarrhea, and nausea.
Summary for Prostacyclin
Prescription only
Tyvaso (treprostinil) is a medication prescribed for adults to treat high blood pressure in the lungs. This medication works to open up blood vessels leading to the lungs to help your body get more oxygen. Tyvaso (treprostinil) is available as a nebulizer and a dry powdered inhaler (DPI). This medication is typically only available at specialty pharmacies, so your provider will need to help set that up for you.